Herpes Zoster Clinical Trial
Official title:
Herpes Zoster Prevalence in Frailty Consultations in University Hospital of Toulouse
Herpes zoster and post herpetic pain are common causes of morbidity in the elderly. Herpes
zoster is caused by reactivation of the virus varicella zoster of latent infection in
sensory ganglia. The acute phase of herpes zoster usually occurs ≤ 30 days after rash onset.
However, the most common complication of herpes zoster is the post herpetic pain, which is
usually defined as a persistent chronic pain for ≥ 3 months after rash onset. The risk of
herpes zoster in life is 25-30%, but this figure rises to 50% among those aged ≥ 85 years.
Similarly, the risk of experiencing post herpetic pain increases with age.
Despite treatment with antiviral drugs, post herpetic pain has been reported in 10-20% of
all patients with herpes zoster, but its incidence increases significantly in elderly
patients over 60 years. It can be particularly harmful when it occurs on a particular field,
elderly multiple pathologies, fragile and with multiple treatment. In this context of
decompensation "cascade" greatly exacerbate the impact of the initial local disease.
Ophthalmologic involvement is rare but clinically worrisome and generates significant costs.
The annual incidence of herpes zoster in France is estimated at 3.4-4.4 cases per 1 000
people in the general population regardless of the history of Herpes zoster. The highest
incidence concerns people aged 65 and over with an incidence estimated between 8-10 cases
per 1 000 people, representing more than 100 000 cases of herpes zoster.
Due to the increasing number of older people in the French population, the number of herpes
zoster should thus parallel increase in the coming years. The risk factors are well
identified for certain (age, ethnicity ...) but for others less well defined (diabetes,
composite criteria multiple pathologies ...) and insufficient to explain why some people
exposed to the same risk factors will not make shingles during their lifetime.
Post herpetic pain is the leading complication of this disease with a higher risk in
patients over 70 years causing a risk of autonomy loss. In fact, besides the disability of
the pain itself, post herpetic pain often requires a combination of high-dose painkillers.
The main therapeutic classes of analgesics used are antiepileptic in high doses (Gabapentin,
Pregabalin), tricyclic antidepressants (amitriptyline), or opiates. The prevention with
herpes zoster vaccine showed a reduction by 2 of risk and could therefore prevent addiction
caused by induced recurrences of herpes zoster and treatment of post herpetic pain.
A study of importance is needed to further define the prevalence of this disease in the
population of frail elderly and to identify factors associated with the occurrence of herpes
zoster, post herpetic pain and ophthalmic zoster.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03120364 -
Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
|
Phase 3 | |
Completed |
NCT01165203 -
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
|
Phase 2 | |
Recruiting |
NCT06088745 -
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
|
Phase 3 | |
Completed |
NCT01385566 -
A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
|
Phase 1 | |
Completed |
NCT01911065 -
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
|
Phase 4 | |
Completed |
NCT01137669 -
ZOSTAVAX® in Renal Transplant Patients
|
Phase 1 | |
Completed |
NCT00550745 -
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
|
Phase 4 | |
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT00231816 -
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
|
Phase 3 | |
Completed |
NCT02852876 -
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
|
Phase 1 | |
Completed |
NCT05082688 -
Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
|
Phase 2 | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Active, not recruiting |
NCT04091451 -
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles
|
Phase 3 | |
Completed |
NCT02519855 -
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
|
Phase 3 | |
Completed |
NCT04523246 -
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
|
Early Phase 1 | |
Completed |
NCT05047770 -
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
|
Phase 3 | |
Completed |
NCT03314103 -
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
|
Phase 3 | |
Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
Completed |
NCT01954251 -
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
|
Phase 3 |